In a move designed to transform the landscape of non-invasive neurostimulation, Nexalin Technology Inc. has officially completed the acquisition of PONM Inc. from GreenLight Ventures LLC. This strategic transaction, valued at $1.3 million in Nexalin common stock, grants the company full ownership of the digital infrastructure that serves as the backbone of its HALO Clarity program and the Nexalin NeuroCare virtual clinic. By internalizing the software suite responsible for AI-integrated patient monitoring and clinical oversight, Nexalin is effectively positioning itself to accelerate its roadmap toward a pivotal FDA trial for moderate-to-severe insomnia, slated for 2026.
The Core Acquisition: Integrating Hardware and Software
For years, the medical device industry has been shifting away from siloed hardware products toward comprehensive, software-enabled care ecosystems. Nexalin’s acquisition of PONM represents a definitive step in this evolution. Under the terms of the deal, Nexalin has secured full ownership of the PONM platform and an exclusive license to proprietary software features specifically engineered for the HALO program.
The acquired technology is far more than a simple database; it is a sophisticated digital health engine. Its capabilities include:
- AI-Integrated Remote Patient Monitoring: Real-time tracking of physiological and behavioral metrics.
- Treatment Compliance Data Capture: Automated systems to ensure patients are utilizing the HALO device as prescribed.
- Electronic Health Record (EHR) Functionality: Seamless integration with clinical workflows to maintain accurate patient histories.
- Virtual-Clinic Management: Tools designed to facilitate remote physician oversight and patient engagement.
- Real-time Clinical Data Analysis: AI-driven insights that allow clinicians to make informed, data-backed adjustments to patient care plans.
By bringing this technology under its own umbrella, Nexalin eliminates the risks associated with third-party software dependencies, ensuring that its proprietary HALO Clarity device is inextricably linked with a robust digital management layer.
A Chronology of Strategic Advancement
The path to this acquisition has been marked by a deliberate, multi-phase deployment strategy. Nexalin’s journey with this technology began with a focus on proof-of-concept and real-world testing.
The UCSD Deployment
The PONM platform is currently active at the University of California, San Diego (UCSD), where it serves as the foundation for the Nexalin NeuroCare virtual clinic. To date, the integration has successfully supported:
- Device Connectivity: Tracking HALO headset usage with granular precision.
- Clinical Oversight: Streamlining remote prescribing and physician interaction.
- Military Research Support: The deployment of five distinct phases of the Nexalin NeuroCare clinic to support recruitment and data workflows for ongoing military health studies.
Preparing for the Pivotal Trial
With the successful validation of the platform at UCSD, Nexalin is now pivoting toward its most significant regulatory milestone: a 160-participant FDA pivotal trial for the treatment of moderate-to-severe insomnia. This study is expected to begin enrollment in the second quarter of 2026. The acquisition of the PONM platform provides the infrastructure necessary to manage a trial of this scale, ensuring that clinical data capture is standardized, secure, and compliant with FDA expectations for decentralized or hybrid trial designs.
Supporting Data and Technical Significance
The importance of the device-plus-software model cannot be overstated in the context of modern neurostimulation. Unlike traditional pharmaceutical interventions for insomnia, which often involve systemic side effects, the HALO Clarity device utilizes neurostimulation to address the underlying neurological patterns associated with sleep disorders.
However, the efficacy of neurostimulation is often tied to patient adherence and the ability of a physician to titrate treatment based on objective data. The PONM platform solves this by creating a "closed-loop" system. By capturing data on how the patient interacts with the device, the AI-integrated software can provide clinicians with a dashboard of progress. This allows for the adjustment of treatment parameters—a capability that is essential for the FDA’s review process, which increasingly favors devices that offer objective data logging over subjective patient reporting.
Official Responses and Strategic Vision
The acquisition was met with enthusiasm from the leadership teams of both Nexalin and GreenLight Ventures. Mark White, CEO of Nexalin Technology, framed the move as a foundational shift for the company’s commercial future.
"This acquisition gives Nexalin ownership of a critical part of the HALO Clarity ecosystem: the digital platform that connects the device, the patient, the physician, and the clinical-data workflow," White stated. "The PONM platform is already deployed at UCSD and supports the AI-integrated remote-monitoring, clinical-data capture, and virtual-clinic capabilities we believe are essential to scaling HALO Clarity. By bringing this infrastructure under Nexalin ownership, we are strengthening our ability to execute through pivotal trial activities, planned FDA submission, and potential commercial launch."
White further emphasized that the company’s vision is not merely about selling a device, but about providing a superior standard of care. "We believe the future of neurostimulation will be defined not only by the device itself, but by the software, data, and physician-supervised care model around it. This transaction strengthens Nexalin’s control over that full ecosystem and expands what we believe the Company can ultimately offer to patients and providers seeking non-invasive treatment alternatives."
From the partner perspective, Peter Gratale, founder of GreenLight Ventures, noted that the alignment between the two companies remains strong despite the transfer of ownership. "GreenLight has spent years building digital infrastructure for next-generation healthcare technologies, and HALO Clarity is exactly the type of platform our work was designed to support," said Gratale. "With this transaction, Nexalin has the exclusive rights to the platform, while GreenLight remains aligned as both a long-term partner and shareholder."
Long-term Implications: The Path to Commercialization
The implications of this transaction extend far beyond the 2026 clinical trial. By securing the PONM platform, Nexalin has effectively "de-risked" its regulatory strategy.
1. Regulatory Hurdles
FDA approval for Class II or Class III medical devices is notoriously difficult. By maintaining a proprietary, validated software environment that tracks every aspect of treatment, Nexalin is building a "regulatory moat." If the FDA requires data transparency or enhanced patient monitoring as a condition of approval, Nexalin now possesses the internal capability to pivot and adapt its software to meet those needs without having to rely on external software vendors.
2. Scalability and Commercialization
Once the pivotal trial concludes, the transition to commercialization will require an infrastructure capable of supporting thousands of patients simultaneously. The virtual clinic model enabled by the PONM software allows Nexalin to scale without the prohibitive cost of physical clinical facilities. This "hub-and-spoke" model—where the patient uses the device at home while remaining tethered to a physician-monitored virtual clinic—is the gold standard for modern telemedicine.
3. Continued Partnership
The strategic partnership established with GreenLight Ventures ensures that Nexalin does not lose the intellectual capital that built the software. With continued access to GreenLight’s experts in engineering, cybersecurity, and regulatory compliance, Nexalin is well-positioned to iterate on its technology. This is particularly crucial in the field of cybersecurity, where medical devices are increasingly targeted by digital threats. Having a partner specialized in cybersecurity ensures that the HALO Clarity ecosystem will remain resilient against modern data-privacy risks.
Conclusion: A New Era for Nexalin
The acquisition of PONM Inc. is a calculated, forward-thinking move that transforms Nexalin Technology from a hardware manufacturer into a comprehensive digital health provider. As the company prepares for its 160-participant trial, the ownership of the PONM platform will serve as the engine that drives clinical success and regulatory validation.
By integrating hardware precision with software-driven clinical oversight, Nexalin is not just addressing the symptoms of insomnia; it is building the infrastructure of a new, scalable, and highly monitorable form of neurostimulation. With the backing of a strategic partner in GreenLight Ventures and a clear roadmap toward 2026, Nexalin has effectively positioned itself at the forefront of the next wave of non-invasive, physician-supervised digital medicine.
